Role of Multi-modality Imaging in the Assessment of Chemotherapy Related Cardiac Dysfunction Among Cancer Patients

Not yet recruiting

• Conditions: 2D Speckle Tracking Echocardiography; Breast Cancer; Cardiac Magnetic Resonance
• Interventions: Device: Two dimensions speckle tracking and three dimension echocardiography and cardiac magnetic resonance imaging

• Registration Number: NCT06206395
• Lead Sponsor: Assiut University

Brief Summary

The field of oncology has advanced remarkably. Some of the old and new emerging cancer therapies are associated with development of cardiovascular toxicities , which may have the potential to offset the gains in survival obtained with this cancer treatment advances. Much of the focus on cardiovascular toxicities has been in the early detection of myocardial damage and prediction of cancer therapeutics-related cardiac dysfunction (CTRCD). The main strategy for these patients is timely diagnosis and treatment of high-risk individual Cardiac dysfunction associated with cancer treatment is the main cause of mortality in cancer survivors. The mortality rate is recorded to be up to 60% in the first two years after therapy. The most commonly associated drugs with cardiotoxicity are anthracycline (AC) and monoclonal antibodies (such as trastuzumab). Other new agents, such as vascular endothelial growth factor (VEGF) inhibitors, immunotherapies, and proteasome inhibitors, can also cause cardiac dysfunction .

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2023-09-25
• Status Verified: 2024-01
• Study First Submitted QC: 2024-01-04
• Last Update Submitted: 2024-01-04
• Study First Posted: 2024-01-16
• Last Update Posted: 2024-01-16
• Study Start: 2024-02-01
• Primary Completion: 2025-03-01
• Study Completion: 2025-05-01

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 190

Inclusion Criteria

• Cancer patients ≥ 18 years of age, and scheduled to receive chemotherapy will be included.

Exclusion Criteria

• Contraindications to CMR (e.g.: patients with pacemakers, defibrillators or other implanted electronic devices).
• Life expectancy ≤ 12 months.
• Participating in another oncology clinical trial;
• Prior exposure to chemotherapy;
• History of active or prior cardiac disease (e.g., myocardial infarction, heart failure or base line left ventricular ejection fraction less than 55%).

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Cancer patients receiving chemotherapeutic drugs	Two dimensions speckle tracking and three dimension echocardiography and cardiac magnetic resonance imaging	Cancer patients ≥ 18 years of age, and scheduled to receive chemotherapy will be included.

Primary Outcome Measures

Name	Time	Method
Determine and compare the role of 2D speckle tracking vs. 3D echocardiography in assessment of early LV systolic dysfunction in patients receiving different chemotherapy combinations	up to 6 months after starting chemotherapy	All patient will be undergo both 2D and 3D echocardiography before and after treatment to detect early LV systolic dysfunction.

Trial Locations

Locations (1)

Assiut University-Cardiovascular department; 🇪🇬 Assiut, Egypt